Home » Stocks » Anika Therapeutics

Anika Therapeutics, Inc. (ANIK)

Stock Price: $34.18 USD 1.04 (3.14%)
Updated Aug 5, 2020 12:21 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 485.43M
Revenue (ttm) 125.54M
Net Income (ttm) 28.48M
Shares Out 14.20M
EPS (ttm) 0.79
PE Ratio 43.27
Forward PE 67.57
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $34.18
Previous Close $33.14
Change ($) 1.04
Change (%) 3.14%
Day's Open 33.68
Day's Range 33.59 - 34.46
Day's Volume 19,284
52-Week Range 22.01 - 75.72

More Stats

Market Cap 485.43M
Enterprise Value 414.88M
Earnings Date (est) Oct 21, 2020
Ex-Dividend Date n/a
Shares Outstanding 14.20M
Float 13.30M
EPS (basic) 2.02
EPS (diluted) 0.79
FCF / Share 1.91
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.31%
FCF Yield 5.58%
Payout Ratio n/a
Shares Short 2.11M
Short Ratio 16.38
Short % of Float 17.34%
Beta 1.18
PE Ratio 43.27
Forward PE 67.57
P/FCF Ratio 17.93
PS Ratio 3.87
PB Ratio 1.76
Revenue 125.54M
Operating Income 11.34M
Net Income 28.48M
Free Cash Flow 27.07M
Net Cash 70.55M
Net Cash / Share 4.97
Gross Margin 68.39%
Operating Margin 9.03%
Profit Margin 22.70%
FCF Margin 21.56%
ROA 2.66%
ROE 4.20%
ROIC 19.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$51.00*
Low
51.0
Current: $34.18
High
51.0
Target: 51.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11510611310393.0010675.0871.3664.7855.56
Revenue Growth8.58%-6.93%9.71%11.16%-11.93%40.64%5.22%10.16%16.6%-
Gross Profit85.8674.2886.0679.3571.9584.6752.3242.3737.9931.73
Operating Income34.2521.7545.7350.6148.1361.4532.6119.7213.977.54
Net Income27.1918.7231.8232.5530.7638.3220.5811.768.474.32
Shares Outstanding14.1214.4414.5814.6814.9314.6814.0913.2613.0612.62
Earnings Per Share1.891.272.112.152.012.511.390.820.620.32
EPS Growth48.82%-39.81%-1.86%6.97%-19.92%80.58%69.51%32.26%93.75%-
Operating Cash Flow37.0134.9240.8124.4539.9139.9825.1710.5510.177.85
Capital Expenditures-2.83-4.66-8.98-14.01-9.23-1.55-0.25-1.50-1.40-2.78
Free Cash Flow34.1830.2631.8310.4330.6938.4324.919.048.775.07
Cash & Equivalents18515915712513810763.3344.0735.7828.20
Total Debt21.37------9.6011.2012.80
Net Cash / Debt16415915712513810763.3334.4724.5815.40
Assets331279283240236193156142133129
Liabilities42.3315.3819.1317.4724.9014.7120.4133.1438.0843.75
Book Value28826426322321117813610994.7685.19
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Anika Therapeutics, Inc.
Country United States
Employees 154
CEO Cheryl R. Blanchard

Stock Information

Ticker Symbol ANIK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ANIK
IPO Date April 29, 1993

Description

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.